CTRI/2009/091/000243尚未招募3 期
A multicentre, multinational, randomizedm Double-Blind, Placebo Controlled, crossover trial to evaluate efficacy and safety of Fentanyl TAIFUN ® treatment after titrated dose administration for breakthrough pain in cancer patients on maintenance opioid therapy
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •"Inclusion Criteria : 1. Age 18 years or over.
- •2. A medically documented diagnosis of cancer.
- •3. Use of a fixed around-the-clock dose of an opioid or a fixed combination of opioids as maintenance therapy for pain relief with a dose equivalent of at least 60 mg of oral morphine/day, or at least 25 µg of transdermal fentanyl/hour, or at least 30 mg of oxycodone daily or at least 8 mg of oral hydromorphone daily. 4. Current opioid treatment for at least 7 days prior to the randomization.
- •5. Current use of opioid medication for BTP. 6. At least one BTP episode per Day with peak intensity of at least 4 on the numerical pain scale (NPS) at pain onset. No more than 4 BTP episodes per day. BTP is defined as a transitory increase in pain to greater than moderate intensity which occurs on a baseline pain of moderate intensity or less.
- •7. The flow rate of inhalation of at least 20 L/min assessed by inspiratory flow meter (the highest of two readings will be used).
- •8. Written informed consent
排除标准
- •"Exclusion Criteria: 1. Uncontrolled or rapidly increasing BTP
- •2. Symptomatic intracranial tumors or cerebral metastases.
- •3. Persistent, symptomatic asthma despite medication, as defined by daily symptoms, frequent exacerbations, frequent nocturnal asthma symptoms, predicted FEV1 <60% or personal best PEFR < 60%.
- •4. Patients unable to use the inhaler (Based on Investigator?s opinion)
- •5. Inadequate lung function, as defined by PEFR < 60 %
- •6. Hypersensitivities, allergies or contraindications to fentanyl or study medication components
- •7. A recent history of alcohol or substance abuse (in the past 1 year).
- •8. Radiotherapy to the thorax within 30 days of the beginning of the titration phase.
- •9. Cognitive impairment or any neurological or psychiatric disease which could compromise the ability of the patient to complete the assessments.
- •10. Participation in any clinical study with experimental drug within 30 days of the randomization, except participation in prior Fentanyl TAIFUN® studies.
- •11. 11.Any clinical condition [e.g. severe hepatic impairment defined by:
- •(1) serum total bilirubin higher than 3 x upper limit of normal (ULN) and/or,
- •(2) serum alanine aminotransferase and serum aspartate aminotransferase higher than 10 x ULN,
- •(3) serum albumin lower than 28 g/L in conjunction with either (1) or (2)],
- •or medical history which, in the opinion of the investigator would not allow for the safe completion of the study or the safe administration of the study drug (e.g. elderly or cachectic patient on the lowest dose of maintenance opioid therapy).
- •12. Pre-menopausal women (last menstruation < 1 year prior to the screening visit) who:
- •? are not surgically sterile and/or
- •? have a positive pregnancy test at baseline visit and/or
- •? are of childbearing potential and are not practicing an acceptable means of birth control or do not plan to continue using this method throughout the study and/or are nursing
研究者
相似试验
进行中（未招募）
不适用
A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH) - N/APulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2006-001464-23-CZPfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ106
进行中（未招募）
1 期
A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects, aged 18 years and above, with pulmonary arterial hypertension (PAH) - N/APulmonary Arterial HypertensionEUCTR2006-001464-23-GBPfizer Ltd103
进行中（未招募）
不适用
A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH) - N/APulmonary Arterial HypertensionEUCTR2006-001464-23-GRPfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ106
进行中（未招募）
不适用
A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg three times daily or placebo when added to bosentan in the treatment of adult subjects, withpulmonary arterial hypertension.MedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial HypertensionEUCTR2006-001464-23-DEPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK106
进行中（未招募）
1 期
A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, and safety of venglustat in late-onset GM2Tay-Sachs diseaseSandhoff diseaseMedDRA version: 20.0Level: PTClassification code 10043147Term: Tay-Sachs diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10081314Term: Sandhoff diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002375-34-FRGenzyme Corporation83